Introduction
Antineoplastic therapies, including chemotherapy, can cure some cancers. Emerging evidence suggests that chemotherapy may induce apoptosis in tumor cells 1 while there is a pause in the cell cycle of their normal cell counterparts. Apoptosis is a genetically encoded cell death program defined by characteristic morphologic and biochemical changes, and these phenomena allow scavenger phagocytes, including immature dendritic cells (DCs), to recognize and engulf apoptotic cells. 2, 3 DCs are professional antigen-presenting cells that induce T-cell responses 4 and we must consider how they could be used for immunotherapy to stimulate an immune response against tumors or infectious agents. They acquire antigens in peripheral tissues, then travel to lymph nodes, and present antigens to lymphocytes. Many studies show that DCs migrate constitutively from peripheral tissues in the absence of any antigenic or inflammatory stimuli, although migration is enhanced by such stimuli. 5 Exogenous antigens are generally taken up by antigen-presenting cells and presented with major histocompatibility complex (MHC) class II molecules. However, exogenous antigens have been reported to enter the class I presentation pathway in vivo (crosspresentation). Several reports have attributed such presentation to DCs in which exogenous antigens can access the class I pathway. 6 Such cross-priming has been shown to induce cytotoxic T lymphocytes (CTL) to tumor antigens, 7, 8 and tissue-associated self-antigens released during cellular destruction. 9 Several recent studies have also shown that DCs can endocytose apoptotic cells and present peptides derived from these on MHC class I and II.
Materials and Methods

Animals and Cell Line
Six-to 10-week-old female BALB/c mice were obtained from Japan SLC (Shizuoka, Japan), and kept in specific pathogen-free animal facilities with controlled temperature and humidity under a 12:12-h light/dark cycle. A murine adenocarcinoma cell line, CT26, established from a chemically induced colon carcinoma in a BALB/ c mouse, was kindly supplied by Shionogi (Osaka, Japan).
Evaluating the Antitumor Effects of Mitomycin C In Vivo
BALB/c mice were shaved over the right flank and injected intradermally (i.d.) with 1 ϫ 10 6 CT26 cells in 100 µl phosphate-buffered saline (PBS). The tumorbearing mice were randomly assigned into two groups 5 days later. The mice in one group were injected intraperitoneally (i.p.) with 2 mg/kg mitomycin C (MMC; kindly provided by Kyowa Hakko Kogyo, Tokyo, Japan) in 100 µl PBS. The mice in the other group were injected i.p. with 100 µl PBS alone. Injections were given three times every 3 days.
After the inoculation, tumor growth was monitored weekly for 39 days by measuring two perpendicular tumor diameters with calipers. Tumor volumes were calculated according to the following formula:
(tumor volume) ϭ (the major axis) ϫ (the minor  axis)  2 mm   3 This formula is adopted in all experiments in this paper. Statistical analysis was performed using repeatedmeasures analysis of variance (ANOVA).
Apoptosis Induced by MMC In Vitro and In Vivo
One million CT26 cells were incubated in RPMI 1640 (Nissui, Tokyo, Japan) with or without 100 µg/ml MMC for 45 min, then washed three times. Some of the treated CT26 cells were stained with the Annexin V-FITC Apoptosis Detection kit (MBL, Nagoya, Japan), which can detect apoptotic cells in the early stage as Annexin-V BALB/c mice were inoculated with 1 ϫ 10 6 cells (i.d.) and, 10 days later, the tumor-bearing mice were given 0, 2, or 4 mg/kg MMC in 100 µl PBS (i.p.). Tumors were resected 2 days later, fixed in 4% paraformaldehyde for 6 h, dehydrated in 30% sucrose overnight, then embedded in OCT compound (Tissue Tek; Sakura Finetechnical, Tokyo, Japan) and frozen on dry ice. Cryostat sections, 6 µm thick, were thaw-mounted on slides, air-dried, and stored at Ϫ80°C until use. The sections were stained with anti-single-stranded DNA antibody (Dako, Tokyo, Japan) 11 for 1 h at 37°C. After being washed in PBS, they were stained with fluorescein isothiocyanate (FITC)-labeled antirabbit Ig (Dako) for 1 h at 37°C, washed in PBS, and examined by fluorescent microscopy.
Culture of DCs
Bone marrow from the femurs and tibiae of BALB/c mice were flushed with PBS using a syringe. On day 0, bone marrow-derived cells were seeded at 2 ϫ 10 6 per 100-mm dish (Iwaki Glass, Funabashi, Japan) in 10 ml of RPMI 1640 containing 200 U/ml murine recombinant granulocyte/macrophage colony-stimulating factor (rmGM-CSF, kindly provided by Kirin Brewery, Maebashi, Japan) supplemented with 10% FBS and 50 µM 2-mercaptoethanol (2-ME). On day 3, 10 ml of the same fresh medium was added. On days 6 and 8, half of the culture supernatant was aspirated, centrifuged, and the cell pellet was resuspended in 10 ml fresh medium containing 200 U/ml rmGM-CSF and taken back into the original plate. On day 10, floating cells were collected and used as DCs. 12 
Immunization and Induction of Protective Immunity
For immunization, BALB/c mice were injected i.p. twice, at weekly intervals, with 1 ϫ 10 6 MMC-treated CT26 cells, 5 ϫ 10 5 DCs, or a mixture of 1 ϫ 10 6 MMCtreated CT26 cells and 5 ϫ 10 5 DCs, in 100 µl PBS, respectively. For the experiment on protective immunity, 1 ϫ 10 6 CT26 cells were inoculated into the right flank of immunized mice (i.d.) 2 weeks after the last immunization. Tumor growth was monitored weekly and tumor volume was calculated as described above. The number of mice that rejected CT26 cells in the three groups was counted and the difference was analyzed using the 2 -test, 6 weeks after tumor inoculation.
Cytokine Secretion Assay
Splenocytes from immunized mice that rejected CT26 cells were collected 6 weeks after the inoculation. Splenocytes (2 ϫ 10 6 /ml) were cocultured with MMCtreated CT26 cells (2 ϫ 10 4 /ml) in a 24-well plate (Iwaki Glass). Supernatants (100 µl) were collected 2 days later and the interferon (IFN)-γ level was measured in duplicate using an IFN-γ enzyme-linked immunosorbent assay (ELISA) kit (BioSource International, Camarillo, CA, USA). 13 Statistical analysis was done using one-way ANOVA.
Cytotoxic T-Lymphocyte Activity
Splenocytes from immunized mice that rejected CT26 cells collected 6 weeks after the inoculation. Splenocytes (1 ϫ 10 6 /ml) were cocultured with MMCtreated CT26 cells (1 ϫ 10 4 /ml) for 5 days in a 100-mm dish in RPMI 1640 supplemented with 10% FBS, 20 U/ml mouse recombinant interleukin (IL)-2 (kindly provided from Shionogi, Osaka, Japan) and 50 µM 2-ME. Cultured splenocytes were collected, and cytotoxic activity against the CT26 cells was measured in triplicate by a 4-h-LDH release assay using the LDHCytotoxic Test kit (Wako, Osaka, Japan) according to the manufacturer's instructions. The cytotoxicity was calculated according to the following formula:
Treatment Model
The 5-day CT26-bearing mice were prepared as described above in "Evaluating the Antitumor Effects of Mitomycin C In Vivo." They were treated with MMC (2 mg/kg, i.p.) on day 0, and with either DCs (5 ϫ 10 5 ) in 100 µl PBS or PBS (100 µl) alone, injected just beneath the tumor (peritumorally) on days 2 and 9. Tumor volumes were monitored weekly for 4 weeks. Statistical analysis was performed using repeated-measures ANOVA.
Results
Antitumor Effects of MMC In Vivo
We first examined the therapeutic effects of MMC against the established tumor in BALB/c mice (Fig. 1 ). Mice were inoculated with 1 ϫ 10 6 CT26 cells 5 days before MMC treatment and randomly divided into two groups. On day 0, the tumor volumes in the two groups did not differ significantly (P ϭ 0.7845). In the PBStreatment group, the tumor volumes of all mice gradually increased, but in the MMC-treatment group, three of six mice rejected the CT26 cells. From day 10 onward, except on day 31, the tumors in the MMC-treated group were significantly smaller than those in the PBS-treated group (P Ͻ 0.05). These results proved that MMC had a therapeutic effect on the CT26-bearing mice.
Apoptosis Induced by MMC In Vitro and In Vivo
MMC is a well-known anticancer drug that blocks DNA replication. To investigate whether apoptosis is involved in the therapeutic effect of MMC, CT26 cells were incubated in vitro in the presence of 100 µg/ml MMC for 45 min. Flow cytometric analysis revealed that 85% of MMC-treated CT26 cells were positive in the Annexin V staining and negative in the PI staining compared with untreated CT26 cells ( Fig. 2A,B) . Thus, most MMC-treated CT26 cells (for 45 min) were in the early stage of apoptosis. When CT26 cells were treated with 100 µg/ml MMC for 45 min, then cultured in fresh medium for 2 days, they were in the early stage of apoptosis (65%) and in the late state of apoptosis or necrosis (35%) (Fig. 2C) . The trypan blue exclusion test showed that the number of MMC-treated CT26 cells decreased by one-eightieth compared with that of untreated cells (on day 2, MMC-treated 2.5 ϫ 10 4 vs untreated 2 ϫ 10 6 ). The microscopic morphology of MMC-treated cells on day 2 showed chromatin condensation as well as fragmentation of the nucleus by Hoechst staining, which was compatible with apoptotic change (data not shown).
Next, we examined if MMC could induce apoptosis in CT26 cells when cultured for 2 days. Higher percentages of apoptosis were seen in the MMC-treated CT26 cells than in the control (Table 1) . It is notable that in the clinical situation, the concentration of MMC is around 0.1-0.01 µg/ml and we confirmed that in this range, MMC can induce apoptosis in vitro. A Untreated CT26 cells were analyzed with Annexin Vfluorescein isothiocyanate (FITC) and propidium iodide (PI) on flow cytometry. The percentages in each quadrant are indicated on the plot. B CT26 cells were treated with 100 µg/ml MMC for 45 min. C CT26 cells were treated with 100 µg/ml MMC for 45 min, then cultured in fresh medium for 2 days. D Mice bearing tumors for 10 days were treated with PBS alone, and 2 days later, the tumors were resected and stained with an anti-single-stranded DNA antibody. E Tumors were stained 2 days after treatment with 2 mg/kg MMC. F Tumors were stained 2 days after treatment with 4 mg/kg MMC
Protective Immunity Induced by DCs or Apoptotic CT26 Cells, or Both
To address the efficacy of DC-based vaccine containing MMC-induced apoptotic CT26 cells, BALB/c mice were immunized i.p. with DCs with or without MMC-treated CT26 cells, then challenged with CT26 cells (i.d.). Complete tumor rejection was seen in 7 of 13 (54%) mice coimmunized with DCs and MMC-treated CT26 cells, while only 1 of 8 (13%) and 3 of 11 (27%) mice were tumor-free after immunization with MMC-treated CT26 alone or DCs alone, respectively ( Table 2) . A higher rejection rate was seen in mice given both DCs and MMC-treated CT26 cells than in those given MMC-treated CT26 cells alone (P ϭ 0.058). The tumor sizes in all three groups were statistically similar to those of the PBS-treated group.
IFN-γ Production and CTL Activity in the Splenocytes of Immunized Mice
To examine the mechanism of protective immunity, we tested the IFN-γ production and CTL response of splenocytes obtained from tumor-rejected mice. Splenocytes from the mice immunized with the mixture of DCs and MMC-treated CT26 cells produced significantly higher levels of IFN-γ (51 pg/ml) than mice immunized with MMC-treated CT26 cells alone (14 pg/ml) or DCs alone (26 pg/ml) (P Ͻ 0.0001) (Fig. 3A) . Splenocytes from the mice not rejecting tumors after treatment with DCs alone, CT26 alone, or both DCs and MMC-treated CT26 cells showed a very low level of We then checked the in vivo effect of MMC on established CT26 tumors. As shown in Fig. 2D and E, MMC, given at 2 and 4 mg/kg, induced apoptosis in the CT26 tumors, but no apoptotic cells were seen in the control tumor (Fig. 2F) .
IFN-γ production, even those from both DCs and MMC-treated CT26 cells (6 pg/ml).
Cultured splenocytes form mice coinjected with DCs and MMC-treated CT26 cells showed significantly (P Ͻ 0.0001) higher CTL activity (37%) against CT26 cells than those from mice immunized with MMC-treated CT26 cells alone (1%) at the Effector/Target (E : T) ratio of 10 : 1 (Fig. 3B) . As described in IFN-γ production, splenocytes from the mice not rejecting tumors after treatment with DCs alone, CT26 alone, and both DCs and MMC-treated CT26 cells had a lower level of CTL activity, even those with DCs and MMC-treated CT26 cells (22% at the E : T ratio of 10 : 1).
Treatment with MMC In Vivo and Peritumoral DC Injection Against CT26-Bearing Mice
CT26-Bearing mice were treated with MMC followed by a peritumoral injection of either DCs or PBS. A significant decrease in tumor volume was seen in the MMC-treatment and DC-treatment groups than in the control group (P Ͻ 0.01, from day 15 to day 28) (Fig. 4) . These data suggest that DCs might collaborate with systemically administered anticancer drugs in vivo.
Discussion
This study showed that the peritumoral injection of DCs can enhance the therapeutic effect of a systemic administration of anticancer drug. Immunization with irradiated or anticancer drug-treated tumor cells can elicit specific immunity against immunized tumor cells, depending on host immune conditions. Several studies have shown not only the cytocidal effects of anticancer drugs such as cisplatin 14 and cyclophosphamide, 15 but also the potential augmentation of antitumor immunity by downregulating suppressor T cells. Furthermore, some biological response modifiers are capable of potentiating the antitumor activity of a variety of chemotherapeutic agents, including cisplatin, 16 although the immunological mechanisms of the effects of this modification are still obscure. Our previous report showed that chemotherapy can augment the effects of transferred CTLs or IL-1 by the immunomodulation of host CD4 ϩ helper T cells. 17 The fact that tumor rejection was induced by DCs coinjected with tumor cells treated with anticancer drugs provides another clue to understanding this synergistic action of DCs and anticancer drugs. Regarding the potential antigen processing by DCs, Bellone et al. reported that processing engulfed apoptotic cells by phagocytes yields T-cell receptor epitopes in the context of MHC class I in vivo. 7 These apoptotic bodies are derived from either infected monocytes 18 or syngeneic tumor cells. 8 Bone marrow-derived DCs are capable of accessing the exogenous antigen through "crosspresentation," a class I-restricted pathway, which is important for immunity against pathogens and tumor cells.
Tong et al. recently reported that the intratumoral injection of DCs combined with high-dose cyclophosphamide (150 mg/kg) resulted in marked tumor suppression using the CT26.CL25 clone, which has been transduced with the -galactosidase gene from Escherichia coli as a model tumor. 19 However, they did not describe the detailed mechanisms of in vivo-induced immunity and protection against wild CT26 tumor cells. In contrast, our data showed that low-dose MMC led CT26 tumor cells into the early stage of apoptosis in vitro and in vivo (Table 1 and Fig. 2B,E,F) . The mice given apoptotic CT26 cells and DCs were relatively resistant to CT26 cells, and a CTL response and IFN-γ production against wild CT26 tumor cells were elicited in the tumor-rejected mice. In another experiment using DC-captured antigen from MMC-treated CT26 cells, there was no difference in growth suppression of wild CT26 between a group coinjected with DCs and MMCtreated CT26 cells and an in vitro-cocultured group with antigen-captured DC, which was cocultured for 1 h with MMC-treated CT26 cells, then washed extensively (data not shown). These results clearly indicate that DCs, when combined with CT26 apoptotic bodies, can generate protective immunity against wild CT26 cells through a T helper 1 (Th1) response.
Some researchers have reported that apoptotic cells alone are not sufficient to supply DCs with the ability to prime CTLs. For the purpose of efficient CTL priming, DCs must become mature, resulting in expression of a high level of costimulatory molecules. However, they insist that phagocytosis of apoptotic cells by DCs failed to allow them to mature, 20 the consequences of which might be the induction of tolerance to self or tumor antigens. 10 Gallucci et al. reported that phagocytosis of apoptotic cells may lead to T-cell immunity if followed by a maturation signal, such as necrotic cells, bacteria, and double-strand RNA. 21 Given these points of view, our results could indicate the possibilities of particular factors. First, MMCtreated tumor cells died through apoptosis, but were led to secondary necrosis when cultured for another 3 days in vitro (Fig. 2C) . MMC-treated tumor cells might be phagocytosed when they are in the apoptotic state, and thereafter DCs might be exposed to the necrotic tumor cells in vivo. Second, CTLs against CT26 cells recognize a single peptide derived from the envelope protein (gp70) of an endogenous ecotropic murine leukemia provirus. 22 The existence of a virus-relating peptide may have some influence on the maturation of DCs. Finally, there are two distinct subsets of DCs: those of myeloid origin and those of lymphoid origin. Some researchers believe that in mice, lymphoid DCs are able to elicit a Th1 response, whereas myeloid DCs elicit a Th2 response. Others believe myeloid DCs that have migrated to the draining lymph nodes may be able to activate both Th1 and Th2 cells. Moreover, the interaction of lymphoid and myeloid DCs may play a role in directing the immune response. 23 We developed DCs from bone marrow cells using GM-CSF, and although the subset and distinct function of these DCs is not specified, they might potentially elicit a Th1 response.
In the treatment model, we demonstrated that the combination therapy of an anticancer drug and DCs could reduce the total dose of an anticancer drug. As shown in Fig. 1 , three injections of 2 mg/kg MMC inhibited tumor growth, but one injection could not (Fig. 4) . However, if combined with DC treatment, just one injection of MMC was enough to reduce the tumor growth. CT26 tumors were led into apoptosis (Fig.  2D ,E) by MMC treatment and followed by phagocytosis and antigen presentation by the injected DCs.
Clinically, 24 several reports have shown that DCs pulsed with immunogenic peptides 25 or cell lysate 26 can induce an antitumor response and augment host immunity. Our model revealed the possible roles of anticancer drugs as generators of apoptotic bodies that are engulfed by DCs as antigens in vivo, as well as their tumoricidal effects. This strategy also contributes greatly to decreasing the time required and the cost of preparing antigens. The precise mechanism of how anticancer drugs affect host immunity is still unclear, but our findings may open a door to a new strategy leading to the successful combination of chemotherapy and a DC-based vaccine.
